
    the study was terminated on june 24th, 2015 due to change in strategy of pf-03084014
    development. there were no safety/efficacy concerns behind the decision.
  
['triple negative breast neoplasms']
['pf-03084014', 'pf-03084014', 'pf-03084014']

        Inclusion Criteria:

          -  Histological or cytological diagnosis of triple negative breast cancer (TNBC) with
             evidence of a) metastatic or b) locally recurrent advanced disease that is not
             amenable to resection or radiotherapy with curative intent.

          -  Availability of an original diagnostic tumor tissue or the most recent metastatic
             tumor biopsies (archival biopsy or de novo biopsy) and a peripheral blood sample for
             Notch receptors genomic profiling

        Exclusion Criteria:

          -  Known brain metastases.

          -  Prior treatment with gamma secretase inhibitor or other Notch signaling inhibitor.
      